Nivolumab/Relatlimab

N/A

Report date: 2023/12/06 10:12:57

Base Information

Drug NameNivolumab/Relatlimab
Drug Alias NameNivolumab+RelatlimabRelatlimab+NivolumabRelatlimab/NivolumabRela+Nivo FDCOPDUALAG +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockersLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 proteinProgrammed cell death protein 1
Therapy Area/IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/03/18
Country/TerritoryCzechiaBelgiumCanada +[40] 
CombinationsYes RelatlimabNivolumab
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdMelanoma Institute Australia +[6] 
Inactive CompaniesN/A
Active IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeL01XY03
Related LinksN/A